We are a young biotech startup and our aim is to develop the next generation of influenza diagnostics. Influenza virus is a big problem. It affects over 10% of the world’s population every year with 650,000 deaths annually. The economical impact is massive: 87 billions US dollars per year, and these numbers continue to grow. The market is dominated by rapid tests with an average sensitivity of only 50%, not enough to be deployed effectively. We are developing a diagnostic solution with higher probability of virus detection and increased diagnostic performance.
Location: United Kingdom, England, London
Employees: 1-10
Investors 1
| Date | Name | Website |
| 25.07.2023 | Startup Fu... | sfccapital... |